Results 231 to 240 of about 185,405 (315)
Follow the Cuts in American Healthcare From 2001 to 2026: A Three-Ledger Analysis of Scrutiny-Control Inversion, Payment Restraint, Revenue Capture, and Official Blame. [PDF]
Klapper AM +5 more
europepmc +1 more source
In this explorative study, the abundance of circular RNA molecules in bone marrow stem cells was found to be elevated in patients with high‐risk myelodysplastic neoplasms, and to be associated with an increased risk of progression to acute myeloid leukemia.
Eileen Wedge +17 more
wiley +1 more source
Association of pandemic-era US county-level policies with adult health and health behaviors. [PDF]
Dore EC +7 more
europepmc +1 more source
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla +9 more
wiley +1 more source
Moral Distress as Subordination by Design: Silence, Containment and the Ethical Erosion of Nursing. [PDF]
Ramsay A, McBain-Rigg K, Hartin P.
europepmc +1 more source
In the present work, we have identified a transcriptional signature based on the differential expression of six genes (BCL2&MAST4, HSH2D&LAT2, METRN&PITPNM2) that would facilitate the early detection of T‐cell acute lymphoblastic leukemia (T‐ALL) patients prone to a poor treatment response and could be implemented at diagnosis, along with other risk ...
Antonio Lahera +11 more
wiley +1 more source
A hierarchical framework for cortical and subcortical gray-matter parcellation across rodents, primates, and humans. [PDF]
Venkadesh S +10 more
europepmc +1 more source
KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan +16 more
wiley +1 more source

